| COVID-19 among patients with multiple sclerosis: a systematic review M Barzegar, O Mirmosayyeb, M Gajarzadeh, A Afshari-Safavi, N Nehzat, ... Neurology: Neuroimmunology & Neuroinflammation 8 (4), e1001, 2021 | 99 | 2021 |
| Clinical characteristics and disability progression of early-and late-onset multiple sclerosis compared to adult-onset multiple sclerosis O Mirmosayyeb, S Brand, M Barzegar, A Afshari-Safavi, N Nehzat, ... Journal of clinical medicine 9 (5), 1326, 2020 | 90 | 2020 |
| COVID-19 infection in a patient with multiple sclerosis treated with fingolimod M Barzegar, O Mirmosayyeb, N Nehzat, R Sarrafi, F Khorvash, AH Maghzi, ... Neurology: Neuroimmunology & Neuroinflammation 7 (4), e753, 2020 | 83 | 2020 |
| Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study M Barzegar, S Vaheb, O Mirmosayyeb, A Afshari-Safavi, N Nehzat, ... Multiple sclerosis and related disorders 52, 102947, 2021 | 67 | 2021 |
| Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis O Mirmosayyeb, V Shaygannejad, S Bagherieh, AM Hosseinabadi, ... Neurological Sciences 43, 233-241, 2022 | 65 | 2022 |
| Efficacy and safety of rituximab in neuromyelitis optica: review of evidence M Etemadifar, M Salari, O Mirmosayyeb, M Serati, R Nikkhah, M Askari, ... Journal of Research in Medical Sciences 22 (1), 18, 2017 | 63 | 2017 |
| Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: the first report from Iran M Barzegar, S Badihian, O Mirmosayyeb, F Ashtari, M Jamadi, S Emami, ... Multiple sclerosis and related disorders 22, 161-165, 2018 | 61 | 2018 |
| Possible role of common spices as a preventive and therapeutic agent for Alzheimer's disease O Mirmosayyeb, A Tanhaei, HR Sohrabi, RN Martins, M Tanhaei, ... International journal of preventive medicine 8 (1), 5, 2017 | 52 | 2017 |
| The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis AN Moghadasi, O Mirmosayyeb, M Barzegar, MA Sahraian, ... Neurological sciences 42 (8), 3093-3099, 2021 | 49 | 2021 |
| An 8-year study of people with multiple sclerosis in Isfahan, Iran: association between environmental air pollutants and severity of disease F Ashtari, N Esmaeil, M Mansourian, P Poursafa, O Mirmosayyeb, ... Journal of neuroimmunology 319, 106-111, 2018 | 49 | 2018 |
| Early predictors of conversion to secondary progressive multiple sclerosis M Barzegar, S Najdaghi, A Afshari-Safavi, N Nehzat, O Mirmosayyeb, ... Multiple sclerosis and related disorders 54, 103115, 2021 | 44 | 2021 |
| The prevalence of migraine in multiple sclerosis (MS): a systematic review and meta-analysis O Mirmosayyeb, M Barzegar, N Nehzat, V Shaygannejad, MA Sahraian, ... Journal of Clinical Neuroscience 79, 33-38, 2020 | 43 | 2020 |
| Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic M Ghajarzadeh, O Mirmosayyeb, M Barzegar, N Nehzat, S Vaheb, ... Multiple Sclerosis and Related Disorders 43, 102222, 2020 | 36 | 2020 |
| Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study V Shaygannejad, E Fayyazi, S Badihian, O Mirmosayyeb, N Manouchehri, ... Journal of Neurology 266, 642-650, 2019 | 35 | 2019 |
| Autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis F Nabizadeh, K Pirahesh, N Rafiei, F Afrashteh, MA Ahmadabad, A Zabeti, ... Neurology and Therapy 11 (4), 1553-1569, 2022 | 33 | 2022 |
| Characteristics of COVID-19 disease in multiple sclerosis patients M Barzegar, O Mirmosayyeb, M Ghajarzadeh, N Nehzat, S Vaheb, ... Multiple Sclerosis and Related Disorders 45, 102276, 2020 | 33 | 2020 |
| Parkinson’s disease and COVID-19: A systematic review and meta-analysis RJ Khoshnood, A Zali, A Tafreshinejad, M Ghajarzadeh, N Ebrahimi, ... Neurological Sciences, 1-9, 2022 | 32 | 2022 |
| A short review on structure and role of cyclic-3’, 5’-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool N Eskandari, O Mirmosayyeb, G Bordbari, R Bastan, Z Yousefi, A Andalib Journal of research in pharmacy practice 4 (4), 175-181, 2015 | 31 | 2015 |
| Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic review O Mirmosayyeb, EM Ghaffary, S Bagherieh, M Barzegar, MS Dehghan, ... Multiple Sclerosis and Related Disorders 60, 103697, 2022 | 29 | 2022 |
| Evaluation of non-motor symptoms and their impact on quality of life in patients with Parkinson’s disease, Isfahan, Iran M Salari, A Chitsaz, M Etemadifar, MR Najafi, O Mirmosayyeb, ... Iranian journal of neurology 16 (3), 118, 2017 | 29 | 2017 |
Vahid ShaygannejadDepartment of Neurology, Isfahan university of medical sciencesEmail yang diverifikasi di med.mui.ac.ir